4 citations
,
July 2022 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone 1% cream is a promising new treatment for acne.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
68 citations
,
May 2024 in “International Journal of Molecular Sciences” Personalized acne treatments and new therapies show promise for better results.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
April 2025 in “International Journal of Molecular Sciences” New treatments for hair loss show promise with advanced therapies and better targeting.
27 citations
,
October 2020 in “Drugs” Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
March 2025 in “Canadian dermatology today.” Clascoterone cream 1% is effective and well-tolerated for treating acne and other related conditions.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
January 2025 in “Dermatology and Therapy” Hormonal therapies effectively treat acne and improve quality of life.
7 citations
,
December 2019 in “American Journal of Clinical Dermatology” Topical therapies show promise for hair loss and acne treatment with minimal side effects.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
April 2025 in “Current Pediatrics Reports” Transgender and gender-diverse teens need specialized skin and mental health care.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
49 citations
,
November 2013 in “JAMA dermatology” Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
February 2023 in “Reactions Weekly”
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
5 citations
,
February 2016 in “International Journal of Cancer” Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.